Hidradenitis Suppurativa Pipeline Summary

DelveInsight’s, “Hidradenitis Suppurativa - Pipeline Insight, 2026” report provides comprehensive insights about 46+ companies and 50+ pipeline drugs in Hidradenitis Suppurativa pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Hidradenitis Suppurativa: Understanding

Hidradenitis Suppurativa: Overview

Hidradenitis suppurativa (HS), also known as acne inversa, is a chronic, recurrent, and debilitating inflammatory skin disorder characterized by painful, deep-seated nodules, abscesses, draining sinus tracts (skin tunnels), and fibrotic scarring. The disease primarily affects intertriginous regions rich in apocrine glands, including the axillae, groin, perianal, perineal, and inframammary areas. HS significantly impairs quality of life due to chronic pain, malodorous drainage, recurrent flare-ups, and permanent scarring, often leading to considerable psychosocial distress.

The exact cause of HS remains incompletely understood, but the disease is considered multifactorial, resulting from the interplay of genetic, environmental, hormonal, and behavioral factors. Approximately one-third of patients report a positive family history, suggesting a hereditary predisposition, with mutations affecting the ?-secretase/Notch signaling pathway identified in some families. Environmental risk factors such as obesity, smoking, and mechanical friction contribute to disease onset and severity by promoting follicular occlusion and inflammation. Hormonal influences, particularly androgen-related changes, are also believed to contribute, as evidenced by disease onset after puberty and symptom fluctuations associated with the menstrual cycle.

The pathogenesis of HS begins with occlusion of the hair follicle, followed by follicular rupture and the release of keratin, bacteria, and cellular debris into the surrounding dermis. This initiates an exaggerated innate and adaptive immune response characterized by infiltration of neutrophils and lymphocytes, resulting in chronic inflammation, abscess formation, tissue destruction, and the development of sinus tracts and fibrotic scars. Dysregulated immune signaling, including increased expression of pro-inflammatory cytokines such as tumor necrosis factor-? (TNF-?), interleukin (IL)-1, IL-17, and IL-23, plays a central role in sustaining inflammation, providing the rationale for the development of targeted biologic therapies.

HS is primarily a clinical diagnosis, based on the presence of characteristic lesions (deep nodules, abscesses, sinus tracts, and scarring), their typical distribution in intertriginous areas, and the chronic or recurrent nature of the disease. Disease severity is commonly classified using the Hurley staging system, which guides treatment decisions. Although no specific laboratory test confirms HS, biopsy may be performed when the diagnosis is uncertain or to exclude malignancy, while bacterial cultures are generally reserved for suspected secondary infections. Imaging modalities, particularly ultrasonography and magnetic resonance imaging (MRI), may be useful in identifying deep sinus tracts and assessing extensive disease before surgical intervention.

Management of HS aims to reduce inflammation, alleviate pain, prevent new lesion formation, and minimize disease progression and scarring. Treatment is individualized according to disease severity and includes lifestyle modifications such as smoking cessation and weight reduction, alongside medical therapies including topical and systemic antibiotics, corticosteroids, hormonal therapies, and biologic agents.

"Hidradenitis Suppurativa- Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Hidradenitis Suppurativa pipeline landscape is provided which includes the disease overview and Hidradenitis Suppurativa treatment guidelines. The assessment part of the report embraces, in depth Hidradenitis Suppurativa commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Hidradenitis Suppurativa collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Hidradenitis Suppurativa R&D. The therapies under development are focused on novel approaches to treat/improve Hidradenitis Suppurativa.

Hidradenitis Suppurativa Emerging Drugs Chapters

This segment of the Hidradenitis Suppurativa report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Hidradenitis Suppurativa Emerging Drugs

• Sonelokimab: MoonLake Immunotherapeutics/ Merck

Sonelokimab is an investigational, humanized single-chain nanobody developed by MoonLake Immunotherapeutics for the treatment of multiple IL-17-driven inflammatory diseases. It is a tri-specific molecule that simultaneously neutralizes interleukin-17A (IL-17A) and interleukin-17F (IL-17F) while binding to human serum albumin (HSA) to extend its half-life. By inhibiting both IL-17A and IL-17F, Sonelokimab aims to provide broader suppression of inflammatory signaling than agents targeting IL-17A alone. Currently, the drug is in the Phase III stage of its development for the treatment of Hidradenitis Suppurativa.

• Abdakibart: Avalo Therapeutics

Abdakibart is an investigational humanized IgG4 monoclonal antibody being developed for the treatment of moderate-to-severe hidradenitis suppurativa (HS). The therapy selectively targets and neutralizes interleukin-1 beta (IL-1?), a key pro-inflammatory cytokine that plays a central role in the pathogenesis of HS by driving innate immune activation, neutrophil recruitment, and chronic inflammation within affected skin lesions. By inhibiting IL-1? signaling, the drug aims to suppress the inflammatory cascade responsible for abscess formation, nodule development, and disease progression, potentially offering a novel therapeutic approach for patients with HS. Currently, the drug is in the Phase II stage of its development for the treatment of Hidradenitis Suppurativa.

• SBT777101: Sonoma Biotherapeutics

SBT777101 is an investigational autologous regulatory T-cell (Treg) therapy being developed for the treatment of hidradenitis suppurativa (HS). The therapy utilizes genetically engineered patient-derived Tregs designed to enhance their stability and immunosuppressive function at sites of chronic inflammation. Its mechanism of action focuses on restoring immune tolerance by suppressing aberrant inflammatory immune responses and reducing the production of pro-inflammatory cytokines that contribute to HS pathogenesis. By re-establishing immune homeostasis rather than broadly suppressing the immune system, SBT777101 has the potential to provide a targeted and durable therapeutic approach for patients with HS. Currently, the drug is in the Phase I stage of its development for the treatment of Hidradenitis Suppurativa.

• ELN28: Elasmogen

ELN28 is an investigational multi-specific therapeutic protein being developed by Elasmogen for the treatment of hidradenitis suppurativa (HS). The drug is engineered using Elasmogen's soloMER® protein scaffold technology to simultaneously target multiple inflammatory pathways implicated in HS. Although the complete mechanism of action has not been publicly disclosed, ELN28 is designed to modulate key pro-inflammatory mediators involved in chronic skin inflammation, with the goal of reducing inflammatory lesions while improving efficacy over single-target biologics. The multi-specific approach aims to provide broader control of the dysregulated immune response that drives HS while maintaining a favorable safety profile. Currently, the drug is in the Preclinical stage of its development for the treatment of Hidradenitis Suppurativa.

Further product details are provided in the report……..

Hidradenitis Suppurativa: Therapeutic Assessment

This segment of the report provides insights about the different Hidradenitis Suppurativa drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Hidradenitis Suppurativa

There are approx. 46+ key companies which are developing the therapies Hidradenitis Suppurativa. The companies which have their Hidradenitis Suppurativa drug candidates in the most advanced stage, i.e. Phase III include, MoonLake Immunotherapeutics, and others.

• Phases

DelveInsight’s report covers around 50+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration

Hidradenitis Suppurativa pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

• Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Hidradenitis Suppurativa: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Hidradenitis Suppurativa therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Hidradenitis Suppurativa drugs.

Hidradenitis Suppurativa Report Insights

• Hidradenitis Suppurativa Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Hidradenitis Suppurativa Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Hidradenitis Suppurativa drugs?
• How many Hidradenitis Suppurativa drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Hidradenitis Suppurativa?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Hidradenitis Suppurativa therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Hidradenitis Suppurativa and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• MoonLake Immunotherapeutics
• Avalo Therapeutics
• Sonoma Biotherapeutics
• Elasmogen
• Incyte Corporation
• Takeda Pharmaceutical Company Limited.
• Sanofi
• Almirall.
• Eli Lilly and company
• Novartis AG

Key Products

• Sonelokimab
• Abdakibart
• SBT777101
• ELN28
• Povorcitinib
• Ruxolitinib cream
• Zasocitinib
• Brivekimig
• Eltrekibart (LY3041658)
• Anti-IL-1RAP mAb
• LOU064